evipedia.ai
← Back

Phosphatidylinositol for Health & Longevity

Evidence Review created on 08/22/2026 using AI4L / Opus 5

Also known as: PI, PtdIns, Phosphatidyl Inositol, Inositol Phosphatide

Motivation

Phosphatidylinositol is one of the fat molecules that form the outer skin of every human cell. Cells convert it into a family of short-lived messenger molecules that govern growth, sugar uptake and internal transport. It also rides on the blood particles that carry cholesterol away from artery walls, a process central to long-term cardiovascular health, which is why it has been considered as something to take by mouth rather than only make internally.

It occurs naturally in soybeans, sunflower seeds, eggs, liver and wheat germ, and forms part of the lecithin used throughout the food supply. Purified preparations moved from food ingredient to candidate supplement when a Canadian biotechnology company pursued the compound as a way to raise the protective form of cholesterol; that program stopped short of large-scale testing, and the compound remains a niche product.

This review examines what is known about taking purified phosphatidylinositol by mouth — what happens to it during digestion, what changes have been observed in people and in animals, what harms have been reported, how it is sourced and used, and how thin or solid the underlying evidence is.

Benefits - Risks - Protocol - Conclusion

The resources below give a high-level view of phosphatidylinositol: what it does inside cells, what is known about eating it, and what happened when it was tested as an oral compound.

None of the six priority expert platforms publishes content on phosphatidylinositol itself. Site searches returned only incidental mentions of the phosphoinositide 3-kinase enzyme family in cancer and hormone contexts — the enzymes that phosphorylate the lipid, not the lipid taken by mouth — so the five items above are drawn from the primary and narrative-review literature instead.

Grokipedia

  • Phosphatidylinositol

    A structural and biochemical reference covering synthesis, acyl-chain composition, conversion to phosphoinositides and membrane anchoring; useful background, with no coverage of oral administration or supplementation.

Examine

No Examine article on phosphatidylinositol exists. A direct search of the site returned no results for the compound.

ConsumerLab

No ConsumerLab article on phosphatidylinositol exists. A direct search of the site returned no results for the compound, and no product review has tested phosphatidylinositol content or purity.

Systematic Reviews

No systematic review or meta-analysis has pooled trials of oral phosphatidylinositol, so the papers below instead pool human outcome data on MBOAT7 (also called LPIAT1, the gene for the enzyme that inserts arachidonic acid into phosphatidylinositol; the co-listed TM6SF2 governs liver fat export and sits outside the phosphatidylinositol pathway), the only pathway through which phosphatidylinositol composition is firmly tied to hard clinical endpoints.

The pooled literature therefore covers one side of the trade-off — the liver and cancer outcomes tied to phosphatidylinositol composition — while the other side is unrepresented: no systematic review or meta-analysis addresses the benefits, harms or tolerability of taking phosphatidylinositol by mouth.

Mechanism of Action

Phosphatidylinositol is a glycerophospholipid: two fatty acids on a glycerol backbone, joined by a phosphate to a myo-inositol ring. In animal tissue the chains are typically stearic and arachidonic acid; in soy-derived material, mostly linoleic acid.

Its significance is as a precursor. Lipid kinases phosphorylate the inositol ring to produce phosphoinositides — chiefly PIP2 (phosphatidylinositol 4,5-bisphosphate) and PIP3 (phosphatidylinositol 3,4,5-trisphosphate). Phospholipase C, an enzyme that cleaves phospholipids, splits PIP2 into two messengers that release stored calcium and activate protein kinase C, a central signaling enzyme. PI3K (phosphoinositide 3-kinase, which generates PIP3) heads the insulin and IGF-1 (insulin-like growth factor 1) growth pathway. Phosphatidylinositol also tethers a family of proteins to the cell surface, and its headgroup labels membrane compartments for traffic.

Taken by mouth, it is largely hydrolyzed by pancreatic phospholipase A2 (the pancreatic enzyme that cuts a fatty acid off phospholipids) to lyso-phosphatidylinositol plus a free fatty acid, absorbed in the small intestine and re-acylated. In mice, radiolabeled phosphatidylinositol concentrates in the liver and remains detectable there beyond 48 hours, indicating a residence time of days rather than hours. In plasma it partitions almost exclusively into HDL, raising the particle’s negative charge and stimulating cholesterol efflux through the ABCA1 transporter (a pump that moves cholesterol out of cells), hepatic uptake and biliary excretion.

The competing mechanistic reading is that intestinal hydrolysis is essentially complete, so oral dosing delivers myo-inositol and fatty acids rather than intact phosphatidylinositol, and any benefit belongs to those products.

Historical Context & Evolution

Inositol-containing lipids were isolated from brain and soybean in the 1930s and 1940s, and the first purpose for the purified material was industrial: lecithin, a phospholipid mixture roughly one-tenth phosphatidylinositol, became an emulsifier in chocolate, margarine and baked goods, a role it still holds as food additive E 322.

Biological interest began in 1953, when Mabel and Lowell Hokin observed that pancreatic tissue stimulated with acetylcholine rapidly turned over its inositol phospholipids. Two decades of work turned that observation into the phosphoinositide cycle: Robert Michell proposed in 1975 that the breakdown was the signal rather than a consequence, Michael Berridge and Robin Irvine identified inositol trisphosphate as the calcium-releasing messenger in 1983, and Lewis Cantley’s group described phosphoinositide 3-kinase in 1988.

A nutritional line ran alongside. Rodents fed inositol-poor diets developed fatty liver, and Bruce Holub’s 1982 review argued that dietary inositol and phosphatidylinositol had underappreciated metabolic roles. That framing was taken up in the early 2000s at the University of Ottawa Heart Institute, where Daniel Sparks and colleagues showed phosphatidylinositol driving cholesterol out of cells and into bile in rabbits, then founded Liponex to develop it as CRD5, an oral HDL-raising agent.

Development halted after a second trial. The compound was not shown to be inert; the average effect simply did not reproduce, the highest dose was stopped for tolerability, and the company wound down — leaving clinical benefit open rather than settled.

Expected Benefits

No benefit of oral phosphatidylinositol reaches high or medium confidence: the entire human record is two company-run trials that disagree with each other.

Low 🟩

Increased HDL Cholesterol and Apolipoprotein A-I ⚠️ Conflicted

Oral phosphatidylinositol raised HDL cholesterol and apolipoprotein A-I (HDL’s main protein) in the first randomized human trial, dose-dependently and only when taken with food. A larger trial in dyslipidemic patients (abnormal blood fat levels) found no significant average rise. Mechanism: enrichment of HDL with phosphatidylinositol, accelerating cholesterol efflux.

Magnitude: HDL cholesterol rose 13% at 2.8 g/day and 18% at 5.6 g/day over two weeks in 16 fed, normolipidemic adults; in 56 dyslipidemic patients the mean rise at 1 g and 3 g was under 5% and not significant.

Reduced Fasting Triglycerides

In the same trial, the higher dose taken with food lowered plasma triglycerides substantially; the lower dose did not. Rodent work attributes this to altered hepatic expression of lipid-synthesis genes. One small, short, unreplicated result; the larger trial listed triglycerides as a secondary endpoint but published no figure.

Magnitude: A 36% fall in plasma triglycerides at 5.6 g/day taken with food over two weeks; no significant change at 2.8 g/day.

Speculative 🟨

Hepatic Fat and Body-Weight Support

Basis is animal and mechanistic only: in diet-induced obese mice, oral phosphatidylinositol accumulated in liver, blunted weight gain and lowered aspartate aminotransferase (a liver enzyme). No human trial has measured either outcome.

Support for Neural Membrane Phosphoinositide Pools

Mechanistic only. Brain membranes are phosphoinositide-rich and inositol lipid handling is altered in diabetic neuropathy (nerve damage caused by diabetes); no study has tested whether oral phosphatidylinositol changes neural lipid pools.

Lower Trimethylamine N-oxide Burden Than Choline Phospholipids

Mechanistic. Unlike phosphatidylcholine, phosphatidylinositol carries no choline, so it cannot feed gut production of trimethylamine N-oxide, a metabolite linked to cardiovascular risk. No study has compared the two head-to-head.

Benefit-Modifying Factors

  • MBOAT7 rs641738 genotype: Carriers remodel phosphatidylinositol acyl chains less efficiently. Whether that raises or lowers the response to dietary phosphatidylinositol is untested, and the pooled human evidence on the variant’s own effect is itself conflicted.

  • Baseline HDL cholesterol: The positive result came from normolipidemic adults with room to rise; the null result came from patients with low HDL and high LDL (low-density lipoprotein, the cholesterol-carrying particle linked to plaque). Baseline state may invert the effect.

  • Sex: No trial reported results separately by sex. Women carry higher baseline HDL cholesterol and apolipoprotein A-I, so an equivalent absolute rise represents a smaller proportional change, but this remains an inference rather than a finding.

  • Fat digestion and absorption capacity: Pancreatic phospholipase A2 and bile are required to process phospholipid. Pancreatic exocrine insufficiency (too little digestive enzyme output), cholestasis (impaired bile flow), extensive bowel resection or high-dose orlistat use would all reduce the amount that ever reaches circulation.

  • Age: Pancreatic enzyme output and bile acid pool size decline with age, which may reduce absorption in older adults; against that, older adults at the top of the target range more often carry the low HDL and raised triglycerides the compound is meant to move.

Potential Risks & Side Effects

Medium 🟥 🟥

Gastrointestinal Intolerance ⚠️ Conflicted

Multi-gram doses of phospholipid can cause nausea, loose stools, cramping and bloating, driven by unabsorbed lipid and its emulsifying action in the gut. Evidence is directly conflicted: the two-week randomized trial reported that all sixteen participants tolerated 2.8–5.6 g daily, while the developer’s Phase I/II report describes suspending the 5 g arm for gastrointestinal adverse events causing unacceptable withdrawal.

Magnitude: Dose-dependent. Absent at 2.8–5.6 g daily for two weeks in sixteen healthy adults, but severe enough at 5 g daily in dyslipidemic patients to end that dose arm; only 11 of the participants assigned to it completed, and no incidence percentage was published.

Low 🟥

Soy Protein Allergen Carryover

Most commercial phosphatidylinositol is purified from soy lecithin, which can retain trace soy protein. The European Food Safety Authority re-evaluation of lecithin raised no systemic safety concern; residual allergenicity is low but not zero, and sunflower-derived material avoids the issue entirely.

Magnitude: Restricted to soy-allergic individuals, and severity tracks residual protein carryover, which varies with refining grade. The literature reports no incidence figure for lecithin-derived phosphatidylinositol.

Altered Absorption of Fat-Soluble Drugs and Nutrients

Phospholipids are deliberately used as absorption enhancers in drug formulation, per a review of phospholipid excipients, raising uptake of poorly soluble compounds. Gram-scale phosphatidylinositol taken with food could therefore shift the absorption of lipophilic drugs and fat-soluble vitamins, an effect never measured for this compound.

Magnitude: Not quantified in available studies. No pharmacokinetic interaction study has co-administered phosphatidylinositol with any drug, so only the class effect of phospholipid excipients is documented.

Speculative 🟨

Omega-6 Fatty Acid Load

Plant-derived phosphatidylinositol carries linoleic acid rather than the arachidonic acid found in tissue phosphatidylinositol. Multi-gram daily intake adds measurably to omega-6 load; whether that matters at these doses is untested.

Lipid Peroxidation of Stored Product

Polyunsaturated phospholipids oxidize on exposure to heat, light and air. Degraded product would deliver oxidized lipid rather than intact phosphatidylinositol; no analysis of commercial supplement oxidation status has been published.

Unknown Consequences of Sustained Precursor Loading

Phosphatidylinositol signaling feeds the target of rapamycin (TOR) growth pathway, whose overactivity shortens lifespan in animals; in roundworms, reducing phosphatidylinositol transfer extends life. Whether dietary loading pushes the same axis in humans is unexamined.

Risk-Modifying Factors

  • MBOAT7 rs641738 genotype: Carriers show impaired phosphatidylinositol remodeling and, in two of three pooled analyses, more liver disease and liver cancer. Whether supplemental substrate helps or aggravates that flux has never been tested.

  • Baseline liver enzymes and triglycerides: Raised alanine aminotransferase (a liver enzyme) or triglycerides signal the fatty liver phenotype in which phosphatidylinositol flux is already abnormal, making both the benefit and the risk less predictable than in metabolically healthy individuals.

  • Sex: No sex-specific safety signal has been reported, and neither phosphatidylinositol trial published a sex breakdown of tolerability, so any difference in gastrointestinal susceptibility remains undocumented for this compound.

  • Pre-existing conditions: Soy allergy, active inflammatory bowel disease, gallbladder disease and pancreatic exocrine insufficiency all raise the chance of gastrointestinal intolerance; advanced kidney failure raises circulating inositol independently of intake.

  • Age: Older adults take more medications at once, so the absorption-enhancing property of phospholipids matters more; reduced pancreatic output also leaves more unabsorbed lipid in the colon, increasing loose stools at a given dose.

Key Interactions & Contraindications

  • Bile acid sequestrants (cholestyramine, colestipol, colesevelam): Caution. These bind lipid in the gut and would reduce phosphatidylinositol absorption and any HDL effect. Separating doses by at least four hours is the standard mitigation for this class.

  • Lipase inhibitors (orlistat): Caution. Blocking fat digestion leaves more phospholipid unabsorbed, compounding steatorrhea (fatty, oily stools) and cramping while removing the benefit. Reducing the phosphatidylinositol dose, or not combining the two, avoids both consequences.

  • Narrow-therapeutic-index lipophilic drugs (cyclosporine, tacrolimus, amiodarone, ketoconazole): Monitor. These fat-soluble drugs have safe and toxic doses sitting close together. Phospholipid excipients raise absorption of poorly soluble drugs, so co-ingestion could raise drug levels. Separating administration by three or more hours and checking levels manages this.

  • Fat-soluble vitamin supplements (A, D, E, K): Caution. Absorption may be enhanced in the same way, which matters where intake is already at the upper limit. Staggering doses or reassessing total intake addresses it.

  • Lipid-lowering agents (statins, ezetimibe, fenofibrate, extended-release niacin): Monitor. Effects on HDL cholesterol and triglycerides would be additive rather than antagonistic; no dose adjustment is established, but a repeat lipid panel distinguishes additive benefit from noise.

  • Other phospholipid supplements (lecithin, phosphatidylcholine, phosphatidylserine): Caution. Gastrointestinal load is additive and dose-dependent. Counting total daily phospholipid across products, rather than each product separately, keeps the combined dose within the tolerated range.

  • Myo-inositol and D-chiro-inositol: Monitor. Digestion of phosphatidylinositol liberates myo-inositol, so combining them raises total inositol exposure; relevant mainly at the multi-gram inositol doses used for metabolic and mood protocols.

Populations who should avoid Phosphatidylinositol:

  • Documented soy allergy, where the product is soy-derived
  • Pregnancy and lactation, where no safety data of any kind exist
  • Chronic kidney disease stage 4–5 (estimated glomerular filtration rate below 30 mL/min/1.73 m², a measure of kidney filtering capacity), where circulating inositol is already elevated
  • Decompensated cirrhosis (Child-Pugh Class B or C, a liver-disease severity score), where bile-dependent phospholipid handling is impaired
  • Severe pancreatic exocrine insufficiency and active inflammatory bowel disease flare
  • Children and adolescents under 18, for whom no dosing or safety data exist

Risk Mitigation Strategies

  • A 1 g starting dose with titration over 2–4 weeks: Gastrointestinal intolerance is the dose-limiting effect and appeared at 5 g daily; approaching the tested 2.8–5.6 g range gradually identifies the personal ceiling before it forces discontinuation.

  • Dosing with a fat-containing meal: In the only positive trial the lipid effect appeared solely in fed subjects, and food reduces the nausea and cramping that unbuffered phospholipid causes. Fasted dosing forfeits benefit and worsens tolerance.

  • Sunflower-derived material where soy allergy exists: Sunflower lecithin carries no soy protein, eliminating allergen carryover entirely rather than reducing it, at equivalent phospholipid content.

  • Three-hour or greater separation from lipophilic medications: Phospholipids enhance absorption of poorly soluble drugs. Timing separation limits unintended increases in levels of agents such as cyclosporine, tacrolimus or amiodarone.

  • Cool, dark, sealed storage within the expiry date: Polyunsaturated phospholipids peroxidize on exposure to heat, light and air. Refrigeration and intact packaging prevent delivery of oxidized lipid instead of intact phosphatidylinositol.

  • Repeat lipid and alanine aminotransferase testing at 4 and 12 weeks: Individual response varied widely and included worsening in the larger trial. Paired baseline and follow-up testing identifies a negative responder before months of exposure accumulate.

Therapeutic Protocol

  • Dose range used in humans: 2.8–5.6 g daily produced the positive lipid result; 1 g and 3 g daily produced no significant average change and 5 g daily proved intolerable. No dose has been validated beyond twelve weeks.

  • Purified-compound approach: Sparks and colleagues at the University of Ottawa Heart Institute, through Liponex, pursued isolated phosphatidylinositol at gram doses, treating the intact lipid as the active agent needing careful oral formulation.

  • Whole-lecithin approach: The nutritional tradition following Holub delivers phosphatidylinositol inside 10–30 g of soy or sunflower lecithin, accepting a lower phosphatidylinositol dose alongside phosphatidylcholine and phosphatidylethanolamine.

  • Timing: Both approaches place the dose with the largest fat-containing meal of the day, since bile flow and pancreatic phospholipase activity are highest then and the effect was food-dependent.

  • Half-life and residence: Absorbed material is re-acylated into tissue pools rather than cleared as a free drug; labeled phosphatidylinositol persists in mouse liver beyond 48 hours, so tissue residence is measured in days.

  • Single versus split dosing: Split dosing across two or three meals is the practical choice at 3 g daily and above, because gastrointestinal intolerance tracks the amount of phospholipid reaching the gut at once rather than the daily total.

  • Genetic considerations: MBOAT7 rs641738 alters phosphatidylinositol acyl-chain remodeling and APOE4 (a variant of the APOE gene governing lipoprotein handling) alters lipid response generally; neither has been used to stratify a phosphatidylinositol protocol.

  • Sex differences: No dosing difference has been established. Neither trial analyzed response or tolerability by sex, so the same range is used for men and women by default rather than by evidence.

  • Age considerations: No age-adjusted protocol exists. Reduced pancreatic and biliary output at the older end of the target range argues for the lower end of the dose range and slower titration.

  • Baseline biomarkers: The positive result came from normolipidemic adults and the null result from dyslipidemic patients, so baseline HDL cholesterol and triglycerides are the variables most likely to determine whether any protocol does anything at all.

  • Pre-existing conditions: Fatty liver, cholestasis and inflammatory bowel disease each alter phospholipid handling or tolerance enough to change the effective dose, though no protocol has been formally adjusted for them.

Discontinuation & Cycling

  • Duration of use: Nothing establishes lifelong use. Both trials ran twelve weeks or less, so continuous use beyond that is extrapolation, and the compound is best understood as an unvalidated short-course intervention.

  • Withdrawal effects: None reported or expected. Phosphatidylinositol is a normal dietary and endogenous constituent, and stopping returns tissue pools to whatever the ordinary diet supplies, without rebound.

  • Tapering: Not applicable. No receptor adaptation, enzyme induction or dependence has been described, so abrupt discontinuation carries no described consequence at any tested dose.

  • Cycling: No cycling scheme has been studied, and no tolerance mechanism is known that cycling would counter. Stopping when a 12-week re-test shows no change is the pragmatic alternative to scheduled cycling.

Sourcing and Quality

  • Source material: Commercial phosphatidylinositol comes from soy or sunflower lecithin. Sunflower avoids soy allergen carryover and genetically modified source concerns; soy remains the cheaper and more widely available starting material.

  • Single-ingredient availability: Purified single-ingredient phosphatidylinositol is essentially unavailable at retail. It reaches consumers inside phospholipid complexes such as BodyBio PC and Seeking Health Optimal PC, or as bulk lecithin.

  • Stated phosphatidylinositol content: Lecithin is roughly 10–15% phosphatidylinositol, so a 1200 mg lecithin softgel supplies well under 200 mg. Products declaring only “phospholipids” make the actual dose impossible to determine.

  • Third-party testing: NSF Certified for Sport, USP Verified and Informed Choice marks confirm identity and contaminant limits. A USP phosphatidylinositol reference standard exists, so laboratories can verify content when a manufacturer chooses to.

  • Formulation and oxidation: Softgels and liquids protect polyunsaturated phospholipid better than loose powders or granules. Nitrogen-flushed packaging, an expiry date and refrigerated liquids indicate a manufacturer managing peroxidation.

Practical Considerations

  • Time to effect: The lipid changes reported in the positive trial appeared within two weeks, and the larger trial read out by twelve. An absent response at twelve weeks is unlikely to emerge later.

  • Common pitfall — dosing fasted: The effect was food-dependent, appearing only in fed subjects. Taking capsules on an empty stomach forfeits whatever benefit exists and worsens the gastrointestinal intolerance that limits the dose.

  • Common pitfall — confusing the phospholipids: Phosphatidylinositol, phosphatidylcholine, phosphatidylserine and myo-inositol are routinely conflated. Almost all published human evidence attributed casually to “phosphatidylinositol” actually concerns one of the other three.

  • Regulatory status: Sold in the United States as a dietary supplement ingredient, not a drug; lecithin is a permitted food additive in the European Union as E 322. No regulator has approved phosphatidylinositol for any medical indication.

  • Absence of organizational positions: No professional society, advocacy organization or guideline body has issued a position on phosphatidylinositol. The only institutional assessment is the European Food Safety Authority’s public review of lecithin, a regulator whose members derive no revenue from the conclusion.

  • Cost, access and payer incentives: Gram doses via lecithin cost a few dollars monthly; purified material is expensive. Competing lipid agents are cheap generics, so no payer has a financial reason to favor or oppose this compound; the structural incentive sits with the developer.

Interaction with Foundational Habits

  • Sleep: No direct interaction. Phosphatidylinositol has no known sedative, stimulant or circadian effect, and neither trial reported sleep changes. The only indirect consideration is timing: dosing with a large late meal to satisfy the food requirement can itself disturb sleep, which favors placing the dose at lunch or an earlier dinner.

  • Nutrition: Direct and potentiating. Dietary fat drives the bile flow and pancreatic phospholipase activity that phospholipid absorption depends on, and the human benefit appeared only in fed subjects. Soybeans, sunflower seeds, eggs, liver and wheat germ supply phosphatidylinositol in food, so a supplement adds to an existing intake rather than filling a gap.

  • Exercise: No established interaction, direct or blunting. Unlike high-dose antioxidants, phosphatidylinositol has no documented effect on training adaptation. Mechanistically it feeds the phosphoinositide 3-kinase pathway that also mediates the muscle response to loading, but no study has tested whether supplementation alters strength, endurance or hypertrophy outcomes in either direction.

  • Stress management: No direct interaction. Phosphatidylinositol is not known to alter cortisol or the stress response, and no trial measured either. The indirect consideration is that inositol phospholipid turnover underlies signaling at several neurotransmitter receptors, which is why myo-inositol has been studied in anxiety — a claim belonging to that compound, not this one.

Monitoring Protocol & Defining Success

Baseline testing establishes whether there is anything to move. A fasting lipid panel with apolipoprotein A-I and apolipoprotein B, liver enzymes, and high-sensitivity C-reactive protein defines the starting point; documented soy allergy determines which source material is appropriate. Because the human data are conflicted and individual response varied widely in the larger trial, the individual’s own baseline is the only meaningful comparator.

Ongoing monitoring follows the intervention’s short response window. Protocols repeat the lipid panel and liver enzymes at 4 weeks, again at 12 weeks, then every 6–12 months if the compound is continued. A response that has not appeared by 12 weeks is unlikely to appear later, since both human trials read out within two to twelve weeks.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
HDL cholesterol 55–80 mg/dL (1.4–2.1 mmol/L) The primary claimed effect Conventional cut-offs are only >40 mg/dL for men and >50 mg/dL for women; 12-hour fast; avoid alcohol for 24 hours beforehand
Apolipoprotein A-I 140–200 mg/dL Particle count behind the HDL number; rose in the positive trial Conventional lower limits are ~110 mg/dL (men) and ~125 mg/dL (women); best paired with HDL cholesterol on the same draw
Triglycerides Below 80 mg/dL (0.9 mmol/L) fasting The second claimed effect and the most food-sensitive marker Conventional threshold is 150 mg/dL; strict 12-hour fast required; a single high-fat meal invalidates the result
Apolipoprotein B Below 80 mg/dL, below 60 mg/dL where risk is high Anchors whether an HDL shift changed anything that matters Conventional labs flag only above 130 mg/dL; non-fasting acceptable; the better companion to HDL than LDL cholesterol
Alanine aminotransferase 10–26 U/L (men), 10–20 U/L (women) Detects the fatty liver phenotype and any hepatic response ALT; a liver enzyme released when liver cells are stressed. Conventional upper limits reach 40–55 U/L, far above the functional range
Gamma-glutamyl transferase Below 20 U/L (men), below 15 U/L (women) Sensitive early marker of hepatic and biliary stress GGT; an enzyme of the bile ducts and liver. Conventional limits run to 60 U/L; rises with alcohol, so record recent intake
High-sensitivity C-reactive protein Below 1.0 mg/L Confirms an inflammatory state is not confounding lipid changes Conventional risk cut-off is 3.0 mg/L; invalid within two weeks of infection or injury; morning draw preferred for consistency

Qualitative markers worth tracking alongside the laboratory values:

  • Stool consistency and frequency, the earliest signal that the dose exceeds tolerance
  • Bloating, nausea or upper abdominal fullness in the hours after dosing
  • Appetite and body weight, given the animal signal on weight gain
  • Energy through the afternoon, as an unblinded but sensitive personal marker
  • Any change in tolerance of fatty meals, which would suggest altered biliary handling

Emerging Research

  • Raising phospholipid content of HDL by another route: A completed phase 2a trial of the endothelial lipase antibody MEDI5884 in 133 adults with stable coronary heart disease (NCT03351738) tested blocking the enzyme that strips phospholipid from HDL — the same endpoint approached from the enzyme side.

  • Phosphorus-31 imaging of membrane phospholipid turnover: A recruiting study (NCT05865652) uses phosphorus-31 magnetic resonance spectroscopy in 22 participants to track membrane phospholipid precursors and breakdown products in living brain — the first non-invasive route to asking whether dietary phosphatidylinositol reaches neural membranes.

  • Testing the phospholipid carrier directly: The ATLANTIS trial (NCT07394517) randomizes 105 adults with mixed dyslipidemia to phospholipid-bound versus triglyceride-bound omega-3 for 24 weeks, testing whether a phospholipid carrier improves incorporation — the bioavailability question that stalled the original development program.

  • Evidence that could weaken the case: Phosphatidylinositol transfer protein-1 integrates insulin/IGF-1 and TOR signaling to negatively regulate lifespan and healthspan in Caenorhabditis elegans - Lin et al., 2026 - found that reducing this transfer protein extends life in roundworms, implying phosphatidylinositol traffic may act against longevity.

  • Phosphatidylinositol remodeling as a liver target: LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover - Tanaka et al., 2021 - shows the pathway diverting phosphatidylinositol into liver fat; whether diet alters that flux is untested.

Conclusion

Phosphatidylinositol is a minor fat in every cell membrane and the raw material for a family of signaling molecules that steer growth, sugar handling and internal transport. Taken as a supplement, most of it is broken apart during digestion, rebuilt, and carried in the blood on the particles that clear cholesterol from tissue.

The case for taking it rests on a narrow and divided base. A short trial in healthy volunteers found a clear rise in the protective cholesterol fraction and a fall in blood fats; a larger and longer trial in people with abnormal blood fats found almost no average change and wide swings between individuals, some of them downward. Both were run by the company developing the compound as a product, which held a financial stake in a positive result. Everything else is animal work, cell work, or reasoning from what the molecule does inside cells.

The harms reported are mostly digestive and clearly tied to dose: the highest daily amount tested was stopped because too many participants withdrew. Beyond that, long-term effects are unknown, and the same signaling pathway the compound feeds is one that shortens life in animals when it runs too hot — a consideration that weighs more for someone taking grams daily for decades than for someone meeting it in food.

The evidence remains genuinely unsettled rather than closed in either direction.

Top - Benefits - Risks - Protocol